1
|
Cottereau AS, Rebaud L, Trotman J, Feugier P, Nastoupil LJ, Bachy E, Flinn IW, Haioun C, Ysebaert L, Bartlett NL, Tilly H, Casasnovas O, Ricci R, Portugues C, Buvat I, Meignan M, Morschhauser F. Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial. Ann Oncol 2024; 35:130-137. [PMID: 37898239 DOI: 10.1016/j.annonc.2023.10.121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2023] [Revised: 09/22/2023] [Accepted: 10/13/2023] [Indexed: 10/30/2023] Open
Abstract
BACKGROUND We investigated the prognostic value of baseline positron emission tomography (PET) parameters for patients with treatment-naïve follicular lymphoma (FL) in the phase III RELEVANCE trial, comparing the immunomodulatory combination of lenalidomide and rituximab (R2) versus R-chemotherapy (R-chemo), with both regimens followed by R maintenance therapy. PATIENTS AND METHODS Baseline characteristics of the entire PET-evaluable population (n = 406/1032) were well balanced between treatment arms. The maximal standard uptake value (SUVmax) and the standardized maximal distance between tow lesions (SDmax) were extracted, the standardized distance between two lesions the furthest apart, were extracted. The total metabolic tumor volume (TMTV) was computed using the 41% SUVmax method. RESULTS With a median follow-up of 6.5 years, the 6-year progression-free survival (PFS) was 57.8%, the median TMTV was 284 cm3, SUVmax was 11.3 and SDmax was 0.32 m-1, with no significant difference between arms. High TMTV (>510 cm3) and FLIPI were associated with an inferior PFS (P = 0.013 and P = 0.006, respectively), whereas SUVmax and SDmax were not (P = 0.08 and P = 0.12, respectively). In multivariable analysis, follicular lymphoma international prognostic index (FLIPI) and TMTV remained significantly associated with PFS (P = 0.0119 and P = 0.0379, respectively). These two adverse factors combined stratified the overall population into three risk groups: patients with no risk factors (40%), with one factor (44%), or with both (16%), with a 6-year PFS of 67.7%, 54.5%, and 41.0%, respectively. No significant interaction between treatment arms and TMTV or FLIPI (P = 0.31 or P = 0.59, respectively) was observed. The high-risk group (high TMTV and FLIPI 3-5) had a similar PFS in both arms (P = 0.45) with a median PFS of 68.4% in the R-chemo arm versus 71.4% in the R2 arm. CONCLUSIONS Baseline TMTV is predictive of PFS, independently of FLIPI, in patients with advanced FL even in the context of antibody maintenance.
Collapse
Affiliation(s)
- A S Cottereau
- Department of Nuclear Medicine, Cochin Hospital, AP-HP, Université Paris Cité, Paris.
| | - L Rebaud
- LITO Laboratory, UMR 1288 Inserm, Institut Curie, Université Paris-Saclay, Orsay; Siemens Healthcare SAS, Saint Denis, France
| | - J Trotman
- Department of Hematology, Concord Repatriation General Hospital, University of Sydney, Sydney, Australia
| | - P Feugier
- Department of Hematology, University Hospital of Nancy and INSERM 1256 University of Lorraine, Vandœuvre-lès-Nancy, France
| | - L J Nastoupil
- Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - E Bachy
- EA LIB (Lymphoma Immuno-Biology), University Claude Bernard Lyon 1, Lyon, France
| | - I W Flinn
- Sarah Cannon Research Institute/Tennessee Oncology, Nashville, USA
| | - C Haioun
- Lymphoïd Malignancies Unit, Henri Mondor Hospital, AP-HP, Créteil
| | - L Ysebaert
- Department of Hematology, IUC Toulouse-Oncopole Toulouse, Toulouse, France
| | - N L Bartlett
- Siteman Cancer Center, Washington University School of Medicine, St. Louis, USA
| | - H Tilly
- Imaging Department, Centre Henri Becquerel, Rouen; QuantIF-LITIS, EA 4108, IRIB, University of Rouen, Rouen
| | - O Casasnovas
- Department of Hematology, F Mitterrand Hospital, Dijon; Inserm 1231, University of Dijon
| | - R Ricci
- LYSARC, Centre Hospitalier Lyon-Sud, Pierre-Bénite
| | - C Portugues
- LYSARC, Centre Hospitalier Lyon-Sud, Pierre-Bénite
| | - I Buvat
- LITO Laboratory, UMR 1288 Inserm, Institut Curie, Université Paris-Saclay, Orsay
| | - M Meignan
- Lysa Imaging, Henri Mondor University Hospital, AP-HP, University Paris East, Creteil
| | - F Morschhauser
- Department of Hematology, University of Lille, CHU Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France
| |
Collapse
|
2
|
Dufour J, Choquet S, Hoang-Xuan K, Schmitt A, Ahle G, Houot R, Taillandier L, Gressin R, Casasnovas O, Marolleau JP, Tamburini J, Serrier C, Perez E, Paillassa J, Gyan E, Chauchet A, Ursu R, Kas A, Soussain C, Houillier C. Systemic relapses of primary CNS lymphomas (PCNSL): a LOC network study. Ann Hematol 2023; 102:1159-1169. [PMID: 36991231 DOI: 10.1007/s00277-023-05108-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2022] [Accepted: 01/19/2023] [Indexed: 03/31/2023]
Abstract
Primary central nervous system lymphomas (PCNSLs) classically remain confined within the CNS throughout their evolution for unknown reasons. Our objective was to analyse the rare extracerebral relapses of PCNSL in a nationwide population-based study. We retrospectively selected PCNSL patients who experienced extracerebral relapse during their follow-up from the French LOC database. Of the 1968 PCNSL included in the database from 2011, 30 (1.5%, median age 71 years, median KPS 70) presented an extracerebral relapse, either pure (n = 20) or mixed (both extracerebral and in the CNS) (n = 10), with a histological confirmation in 20 cases. The median delay between initial diagnosis and systemic relapse was 15.5 months [2-121 months]. We found visceral (n = 23, 77%), including testis in 5 (28%) men and breast in 3 (27%) women, lymph node (n = 12, 40%), and peripheral nervous system (PNS) (n = 7, 23%) involvement. Twenty-seven patients were treated with chemotherapy, either with only systemic targets (n = 7) or mixed systemic and CNS targets (n = 20), 4 were consolidated by HCT-ASCT. After systemic relapse, the median progression-free survival and overall survival (OS) were 7 and 12 months, respectively. KPS > 70 and pure systemic relapses were significantly associated with higher OS. Extracerebral PCNSL relapses are rare, mainly extranodal, and frequently involve the testis, breast, and PNS. The prognosis was worse in mixed relapses. Early relapses raise the question of misdiagnosed occult extracerebral lymphoma at diagnostic workup that should systematically include a PET-CT. Paired tumour analysis at diagnosis/relapse would provide a better understanding of the underlying molecular mechanisms.
Collapse
Affiliation(s)
- J Dufour
- Hôpital Pitié-Salpêtrière, Service de Neurologie 2-Mazarin, APHP, Sorbonne Université, IHU, ICM, Paris, France
| | - S Choquet
- Hôpital Pitié-Salpêtrière, Service d'Hématologie clinique, Paris, France
| | - K Hoang-Xuan
- Hôpital Pitié-Salpêtrière, Service de Neurologie 2-Mazarin, APHP, Sorbonne Université, IHU, ICM, Paris, France
| | - A Schmitt
- Institut de Bergonie, Service d'Hématologie, Bordeaux, France
| | - G Ahle
- Hôpitaux civils de Colmar, Service de Neurologie, Colmar, France
| | - R Houot
- Hôpital Universitaire de Rennes, Service d'Hématologie, Rennes, France
| | - L Taillandier
- Hôpital Universitaire de Nancy, Service de Neurologie, Nancy, France
| | - R Gressin
- Hôpital Universitaire de Grenoble, Service d'Hématologie, Grenoble, France
| | - O Casasnovas
- Hôpital Universitaire de Dijon, Service d'hematologie clinique, Dijon, France
| | - J P Marolleau
- Hôpital Universitaire d'Amiens, Service d'Hematologie clinique, Amiens, France
| | - J Tamburini
- Hôpital Cochin, Service d'Hématologie, Paris, France
| | - C Serrier
- Centre Hospitalier de Perpignan, Service d'Hématologie, Perpignan, France
| | - E Perez
- Hôpital Universitaire de la Réunion, Service d'oncologie-hématologie, Paris, La Réunion, France
| | - J Paillassa
- Hôpital Universitaire d'Angers, Service d'Hématologie, Angers, France
| | - E Gyan
- Hôpital Universitaire de Tours, Service d'Hématologie, Tours, France
| | - A Chauchet
- Hôpital Universitaire de Besançon, Service d'Hématologie, Besançon, France
| | - R Ursu
- Hôpital Saint-Louis, Service de Neurologie à orientation oncologique, Paris, France
| | - A Kas
- Hôpital Pitié-Salpêtrière, Service de Médecine Nucléaire, Paris, France
| | - C Soussain
- Institut Curie, Service d'Hématologie, Saint-Cloud, France and INSERM U932, Institut Curie, PSL Research University, Paris, France
| | - C Houillier
- Hôpital Pitié-Salpêtrière, Service de Neurologie 2-Mazarin, APHP, Sorbonne Université, IHU, ICM, Paris, France.
| |
Collapse
|
3
|
Peignaux-Casasnovas K, Truc G, Rossi C, Casasnovas O. [Role of radiotherapy in haematology]. Cancer Radiother 2021; 25:603-606. [PMID: 34462212 DOI: 10.1016/j.canrad.2021.07.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2021] [Revised: 07/01/2021] [Accepted: 07/10/2021] [Indexed: 10/20/2022]
Abstract
The management of myeloid and lymphoid disease is essentially based on chemotherapy and targeted therapies. Since radiotherapy could be responsible for severe late toxicities, essentially due to conventional bidimensional irradiation techniques, many trials have attempted to omit radiotherapy or to scale down the dose in their therapeutic strategy. Nevertheless, radiotherapy still plays a role for curative or symptomatic purposes.
Collapse
Affiliation(s)
- K Peignaux-Casasnovas
- Département de radiothérapie, centre Georges-François-Leclerc, 1, rue du Professeur-Marion, 21079 Dijon, France.
| | - G Truc
- Département de radiothérapie, centre Georges-François-Leclerc, 1, rue du Professeur-Marion, 21079 Dijon, France
| | - C Rossi
- Service d'hématologie, CHU de François-Mitterrand, 21000 Dijon, France
| | - O Casasnovas
- Service d'hématologie, CHU de François-Mitterrand, 21000 Dijon, France
| |
Collapse
|
4
|
Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn JK, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Gouill S, Oberic L, Robak T, Jain P, Calvo R, Tao L, Dlugosz‐Danecka M. ACALABRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: FINAL RESULTS FROM A PHASE 2 STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.58_2880] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M. Wang
- MD Anderson Cancer Center, University of Texas Lymphoma ‐ Myeloma, Division of Cancer Medicine Houston Texas USA
| | - S. Rule
- Plymouth University Medical School Hematology Plymouth UK
| | - P. L. Zinzani
- Institute of Hematology “Seràgnoli” University of Bologna Experimental, Diagnostic and Specialty Medicine ‐ DIMES Bologna Italy
| | - A. Goy
- John Theurer Cancer Center, Hackensack University Medical Center Oncology Hackensack New Jersey USA
| | - O. Casasnovas
- CHU Dijon ‐ Hôpital d’Enfants Hematology Dijon France
| | - S. D. Smith
- Fred Hutchinson Cancer Research Center, University of Washington Medical Oncology Seattle Washington USA
| | - G. Damaj
- Institut d’Hématologie de Basse‐Normandie Hematology Caen France
| | - J. K. Doorduijn
- Erasmus MC, HOVON Lunenburg Lymphoma Phase I/II Consortium Hematology Rotterdam Netherlands
| | - T. Lamy
- CHU de Rennes Hematology Rennes France
| | - F. Morschhauser
- CHU Lille, ULR 7365 ‐ GRITA ‐ Groupe de Recherche sur les formes Injectables et les Technologies Associées Hematology Lille France
| | - C. Panizo
- Clínica Universidad de Navarra Hematology Pamplona Spain
| | - B. Shah
- Moffitt Cancer Center Malignant Hematology Tampa Florida USA
| | - A. Davies
- Cancer Research UK Experimental Cancer Medicines Centre, University of Southampton Faculty of Medicine Medical Oncology Southampton UK
| | - R. Eek
- Border Medical Oncology Medical Oncology Albury Australia
| | - J. Dupuis
- Unité Hémopathies Lymphoïdes AP‐HP Hôpital Henri Mondor, Hematology Créteil France
| | - E. Jacobsen
- Dana Farber Cancer Institute Harvard Medical School, Medical Oncology Boston Massachusetts USA
| | - A. P. Kater
- Amsterdam University Medical Center Amsterdam, on behalf of Hovon, Hematology, Lymphoma and Myeloma Research Amsterdam Netherlands
| | - S. Gouill
- CHU de Nantes—Hotel Dieu Hematology Nantes France
| | - L. Oberic
- Institut Universitaire du Cancer—Oncopole Toulouse (IUCT‐O) Hematology Toulouse France
| | - T. Robak
- Copernicus Memorial Hospital, Medical University of Lodz Hematology Lodz Poland
| | - P. Jain
- MD Anderson Cancer Center, University of Texas Leukemia Houston Texas USA
| | - R. Calvo
- AstraZeneca, Clinical Development Hematology R&D Oncology Gaithersburg Maryland USA
| | - L. Tao
- AstraZeneca Biostatistics South San Francisco California USA
| | - M. Dlugosz‐Danecka
- Maria Sklodowska‐Curie National Research Institute of Oncology Hematology Krakow Poland
| |
Collapse
|
5
|
Deux J, Meignan M, Chartier L, Judet A, Vercellino L, Casasnovas O, Baud V, Tilly H, Cottereau A, Thieblemont C. HIGH ADIPOSE TISSUE DENSITY IS A NEGATIVE PROGNOSTIC FACTOR IN DLBCL PATIENTS TREATED BY R‐CHOP, INDEPENDENT FROM TMTV AND PS –FROM THE REMARC STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.78_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- J.‐F. Deux
- APHP, Hopital Henri Mondor, Radiologie Creteil France
| | - M. Meignan
- LYSA‐IM, Hopital Henri Mondor LYSA‐IM Paris France
| | | | - A. Judet
- APHP Saint‐Louis Hospital Hemato‐oncology Paris France
| | - L. Vercellino
- APHP Hopital Saint‐Louis Medecine Nucleaire Paris France
| | | | - V. Baud
- Université de Paris NF‐KappaB, différenciaation et Cancer Paris France
| | - H. Tilly
- Centre Henri Becquerel INSERM U1245 Rouen France
| | | | | |
Collapse
|
6
|
Thieblemont C, Deux J, Vercellino L, Chartier L, Casasnovas O, Judet A, Baud V, Tilly H, Cottereau A, Meignan M. DEFINING ULTRA‐HIGH‐RISK DLBCL PATIENTS PRIOR TO INITIAL TREATMENT BASED ON AN INTEGRATIVE HOST AND DISEASE PROGNOSTIC SCORE (FROM REMARC STUDY). Hematol Oncol 2021. [DOI: 10.1002/hon.17_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- C Thieblemont
- APHP, Saint‐Louis Hospital Hemato‐oncology Paris France
| | - J.‐F Deux
- APHP, Hopital Henri Mondor Radiology Paris France
| | - L Vercellino
- APHP, Hopital Saint‐Louis Medecine Nucleaire Paris France
| | | | | | - A Judet
- APHP, Saint‐Louis Hospital Hemato‐oncology Paris France
| | - V Baud
- Université de Paris NF‐KappaB, différenciaation et Cancer Paris France
| | - Hervé Tilly
- Centre Henri Becquerel INSERM U1245 Rouen France
| | | | - M Meignan
- LYSA‐IM Hopital Henri Mondor LYSA‐IM Paris France
| |
Collapse
|
7
|
Maerevoet M, Casasnovas O, Cartron G, Morschhauser F, Thieblemont C, Bouabdallah K, Feugier P, Szablewski V, Becker S, Tilly H. SELINEXOR IN COMBINATION WITH R‐GDP FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL LYMPHOMA: PRELIMINARY RESULTS OF THE SELINDA PHASE IB LYSA STUDY ( EUDRACT NUMBER: 2015‐005612‐15). Hematol Oncol 2021. [DOI: 10.1002/hon.88_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- M. Maerevoet
- Institut Jules Bordet ULB, Hematology Brussels Belgium
| | - O. Casasnovas
- CHU Dijon Bourgogne Hematology and INSERM 1231 Dijon France
| | - G. Cartron
- CHU Montpellier Hematology Montpellier France
| | | | | | | | | | - V. Szablewski
- CHU Montpellier Pathological Anatomy and Cytology Montpellier France
| | - S. Becker
- Centre Henri Becquerel Nuclear Medicine Rouen France
| | - H. Tilly
- Centre Henri Becquerel Hematology Rouen France
| |
Collapse
|
8
|
Al Tabaa Y, Casasnovas O, Baillet C, Bachy E, Virelizier EN, Schiano de Colella JM, Bailly C, Kanoun S, Guidez S, Gyan E, Gressin R, Morineau N, Ysebaert L, Le Gouill S, Tilly H, Houot R, Morschhauser F, Cartron G, Herbaux C. PROSPECTIVE EVALUATION OF LYMPHOMA RESPONSE TO IMMUNOMODULATORY THERAPY CRITERIA (LYRIC) IN GATA TRIAL FROM THE LYSA GROUP. Hematol Oncol 2021. [DOI: 10.1002/hon.157_2880] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- Y. Al Tabaa
- Scintidoc Nuclear Medicine Center Montpellier France
| | | | | | | | | | | | - C. Bailly
- CHU Nantes Nuclear Medicine Nantes France
| | - S. Kanoun
- Oncopole Toulouse Nuclear Medicine Toulouse France
| | - S. Guidez
- CHU Poitiers Hematology Poitiers France
| | - E. Gyan
- CHU Tours Hematology Tours France
| | | | - N. Morineau
- CHD Vendée Hematology La Roche sur Yon France
| | - L. Ysebaert
- Oncopole Toulouse Hematology Toulouse France
| | | | - H. Tilly
- Centre Henri Becquerel Hematology Rouen France
| | - R. Houot
- CHU Rennes Hematology Rennes France
| | | | - G. Cartron
- CHU Montpellier Hematology Montpellier France
| | - C. Herbaux
- CHU Montpellier Hematology Montpellier France
| |
Collapse
|
9
|
Cartron G, Bachy E, Guidez S, Gyan E, Gressin R, Morineau N, Sibon D, Casasnovas O, Le Gouill S, Tilly H, Ysebaert L, Schiano de Colella JM, Feugier P, Virelizier EN, Haioun C, Damaj G, Tarte K, Laurent C, Houot R, Thieblemont C, Morschhauser F, Herbaux C. ATEZOLIZUMAB + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 2 TRIAL FROM LYSA. Hematol Oncol 2021. [DOI: 10.1002/hon.22_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- G. Cartron
- CHU Montpellier Hématologie Cliniqu Montpellier France
| | | | | | | | | | - N. Morineau
- CHD Vendée Hematology La Roche sur Yon France
| | | | | | | | - H. Tilly
- CHB Unicancer Hematology Rouen France
| | | | | | | | | | | | | | | | | | | | | | | | - C. Herbaux
- CHU Montpellier Hématologie Cliniqu Montpellier France
| |
Collapse
|
10
|
Marouf A, Cottereau AS, Kanoun S, Deschamps P, Franchi P, Meignan M, Sibon D, Gastinne T, Borel C, Hammoud M, Sicard G, Gille R, Cavalieri D, Stamatoullas A, Clement L, Lazarovici J, Chauchet A, Fornecker LM, Amorin S, Rocquet M, Raus N, Burroni B, Rubio MT, Casasnovas O, Cartron G, Bouscary D, Brice P, Ghesquieres H, Tamburini J, Deau B. AMAHRELIS : ADCETRIS MAINTENANCE AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN HODGKIN LYMPHOMA : A REAL LIFE STUDY FROM SFGMTC AND LYSA GROUPS. Hematol Oncol 2021. [DOI: 10.1002/hon.101_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- A. Marouf
- Cochin Hospital Paris University Hematology Unit Paris France
| | - A. S. Cottereau
- Cochin Hospital Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris Descartes University Department of Nuclear Medicine Paris France
| | - S. Kanoun
- Institut universitaire du cancer Toulouse‐Oncopole Nuclear Medecine Unit, Toulouse France
| | - P. Deschamps
- Cochin Hospital Paris University Hematology Unit Paris France
| | - P. Franchi
- Cochin Hospital Paris University Hematology Unit Paris France
| | - M. Meignan
- Hôpital Henri Mondor Paris Est University Lymphoma Study Association Imaging Créteil France
| | - D. Sibon
- Necker Hospital Paris University Department of Hematology Paris France
| | - T. Gastinne
- Nantes University Hospital Department of Hematology Nantes France
| | - C. Borel
- Institut universitaire du cancer Toulouse‐ Oncopole Hematology Toulouse France
| | - M. Hammoud
- Lymphoid Malignancies Unit Hôpital Henri Mondor Hematology Creteil France
| | - G. Sicard
- Aix‐Marseille University Hematology Marseille France
| | - R. Gille
- Centre Léon Berard Hematology Lyon France
| | - D. Cavalieri
- Centre Hospitalier Universitaire Estaing Hematology Clermont Ferrand France
| | | | - L. Clement
- CHRU Nancy Brabois Hematology Vandoeuvre Les Nancy France
| | | | | | - L. M. Fornecker
- Strasbourg University Hospital INSERM S‐1113 Hematology Strasbourg France
| | - S. Amorin
- Hopital Saint Vincent de Paul Hematology Lille France
| | - M. Rocquet
- Cochin Hospital Paris University Hematology Unit Paris France
| | - N. Raus
- Hopital Lyon Sud Hematology Pierre Benite France
| | - B. Burroni
- Cochin Hospital APHP, Centre de recherche des Cordeliers Sorbonne University INSERM, Paris University Pathology Paris France
| | - M. T. Rubio
- CHRU Nancy CNRS UMR 7365 Équipe 6 Biopôle de L'Université de Lorraine Hematology Vandoeuvre Les Nancy France
| | - O. Casasnovas
- Dijon University Hospital INSERM UMR 1231 Hematology Dijon France
| | - G. Cartron
- University of Montpellier Hematology Montpellier France
| | - D. Bouscary
- Cochin Hospital Paris University Hematology Unit Paris France
| | - P. Brice
- Saint Louis Hospital Paris university Hematology Paris France
| | | | - J. Tamburini
- Université de Paris Institut Cochin INSERM U1016, F‐75014 Paris Translational Research Centre in Onco‐hematology Faculty of Medicine University of Geneva Hematology 1211 Geneva Switzerland
| | - B. Deau
- Cochin Hospital Paris University Hematology Unit Paris France
| |
Collapse
|
11
|
Gastinne T, Bouabdallah K, Moatti H, Tessoulin B, Shiano del colella JM, Lamy T, Casasnovas O, Borel C, Stamatoullas A, Gac AC, Chaoui D, Feugier P, Delmer A, Bonnet C, Fornecker L, Lazarovici J, Bras F, Ghesquieres H, Meignan M, Traverse Glehen A, Brice P. BRENTUXIMAB VEDOTIN AS CONSOLIDATION TREATMENT IN PATIENTS WITH STAGE I/II CLASSICAL HODGKIN'S LYMPHOMA AND A POSITIVE FDG‐PET AFTER 2 CYCLES OF ABVD: A LYSA PHASE 2 STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.111_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- T. Gastinne
- University Hospital of Nantes Hematology Nantes France
| | - K. Bouabdallah
- Hopital Haut‐Levêque Centre Hospitalier Regional Universitaire de Bordeaux Department of Hematology Pessac France
| | - H. Moatti
- Hôpital saint Louis APHP Université Paris 7 Department of Oncohaematology Paris France
| | - B. Tessoulin
- University Hospital of Nantes Hematology Nantes France
| | | | - T. Lamy
- Rennes University Hospital Department of Clinical Hematology MICA Research Unit Rennes France
| | - O. Casasnovas
- University Hospital F Mitterrand and INSERM 1231 Department of Haematology Dijon France
| | - C. Borel
- IUCT‐Oncopole CHU Toulouse Department of Haematology Toulouse France
| | - A. Stamatoullas
- Centre Henri Becquerel Department of Haematology U918 Rouen France
| | - A. C. Gac
- Centre Hospitalier Universitaire de Caen Institut d'hématologie de Basse‐Normandie Caen France
| | - D. Chaoui
- Centre Hospitalier d'Argenteuil Department of Hematology Argenteuil France
| | - P. Feugier
- Nancy University Hospital Department of Clinical Hematology INSERM 1256 Nancy France
| | - A. Delmer
- University Hospital of Reims Department of Haematology Reims France
| | - C. Bonnet
- CHU Liège, Liège Université Campus Universitaire de Sart Tilman Clinical Hematology Unit Liège Belgium
| | - Luc‐M. Fornecker
- Strasbourg University Hospital Department of Clinical Hematology Strasbourg France
| | - J. Lazarovici
- Institut Gustave Roussy Département des Innovations Thérapeutiques et Essais Précoces Villejuif France
| | - F. Bras
- CHU Henri Mondor Department of Hematology Creteil France
| | - H. Ghesquieres
- Hospices Civils de Lyon Centre Hospitalier Lyon‐Sud and Université Claude Bernard Lyon‐1 Department of Haematology Lyon France
| | - M. Meignan
- Hôpital H Mondor LYSA Imaging Creteil France
| | - A. Traverse Glehen
- Centre Hospitalier Lyon‐Sud Hospices Civils de Lyon Pathology Department cedex, France, Lyon France
| | - P. Brice
- Hôpital saint Louis APHP Université Paris 7 Department of Oncohaematology Paris France
| |
Collapse
|
12
|
Camus V, Belot A, Oberic L, Sibon D, Ghesquières H, Thieblemont C, Fruchart C, Casasnovas O, Michot J, Molina TJ, Bosly A, Joubert C, Haioun C, Delarue R, Tilly H. LONG‐TERM OUTCOMES OF ELDERLY PATIENTS TREATED WITH FRONTLINE R‐CHOP: UPDATE OF THE LNH03‐6B TRIAL. Hematol Oncol 2021. [DOI: 10.1002/hon.96_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- V. Camus
- Centre Henri Becquerel Department of Hematology Rouen France
| | | | - L. Oberic
- IUCT Oncopole Hematology Toulouse France
| | - D. Sibon
- CHU Necker hematology Paris France
| | | | | | | | | | | | | | - A. Bosly
- UCL Mont‐Godinne Hematology Namur Belgium
| | | | - C. Haioun
- CHU Mondor Hematology Créteil France
| | | | - H. Tilly
- Centre Henri Becquerel Department of Hematology Rouen France
| |
Collapse
|
13
|
Cottereau AS, Meignan M, Nioche C, Capobianco N, Clerc J, Chartier L, Vercellino L, Casasnovas O, Thieblemont C, Buvat I. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT†. Ann Oncol 2021; 32:404-411. [DOI: 10.1016/j.annonc.2020.11.019] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2020] [Revised: 11/05/2020] [Accepted: 11/17/2020] [Indexed: 10/22/2022] Open
|
14
|
Morschhauser F, Ghosh N, Lossos I, Palomba M, Mehta A, Casasnovas O, Stevens D, Chitra S, Knapp A, Nielsen T, Oestergaard M, Wenger M, Salles G. EFFICACY AND SAFETY OF OBINUTUZUMAB + LENALIDOMIDE + ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.74_2629] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- F. Morschhauser
- Institute of Hematology-Transfusion; Centre Hospitalier Régional Universitaire de Lille; Lille France
| | - N. Ghosh
- Hematologic Oncology and Blood Disorders; Levine Cancer Institute/Atrium Health; Charlotte NC United States
| | - I. Lossos
- Division of Hematology; Department of Medicine, University of Miami; Miami FL United States
| | - M.L. Palomba
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York NY United States
| | - A. Mehta
- Division of Hematology and Oncology; University of Alabama School of Medicine; Birmingham Alabama United States
| | - O. Casasnovas
- Service d'Hématologie clinique; CHU Dijon Bourgogne - Hôpital François Mitterrand; Dijon France
| | - D. Stevens
- Norton Cancer Institute; Norton Healthcare; Louisville KY United States
| | - S. Chitra
- Product Development Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - A. Knapp
- Product Development Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - T. Nielsen
- Product Development Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - M. Oestergaard
- Oncology Biomarker Development; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - M. Wenger
- Product Development Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - G. Salles
- Haematology Department; Université Claude Bernard de Lyon, Lyon University Hospital; Villeurbanne France
| |
Collapse
|
15
|
Lemonnier F, Safar V, Ferchiou A, Cottereau A, Bachy E, Cartron G, Moles-Moreau M, Delmer A, Bouabdallah R, Voillat L, Parrens M, Casasnovas O, Cacheux V, Réguy C, Tilly H, Meignan M, Gaulard P, de Leval L, Delfau-Larrue M, Haioun C. BONE MARROW INVOLVEMENT, BUT NO BLOOD INVOLVEMENT, IMPAIRS SURVIVAL IN ANGIOIMMUNOBLASTIC T CELL LYMPHOMA: AN ANCILLARY STUDY OF THE REVAIL TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.89_2630] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- F. Lemonnier
- Unité Hémopathies Lymphoïdes, INSERMU955; Université Paris Est, Hôpitaux Universitaires Henri Mondor; Créteil France
| | - V. Safar
- Hématologie; Hôpital Lyon Sud; Pierre Bénite France
| | - A. Ferchiou
- Laboratoire d'immunologie; Université Paris Est, Hôpitaux Universitaires Henri Mondor; Créteil France
| | - A. Cottereau
- Département de Médecine Nucléaire; Hopital Cochin; Paris France
| | - E. Bachy
- Hématologie; Hôpital Lyon Sud; Pierre Bénite France
| | - G. Cartron
- Département d'Hématologie Clinique; CHU Montpellier; Montpellier France
| | | | - A. Delmer
- Service d'Hématologie Clinique; CHU Reims; Reims France
| | - R. Bouabdallah
- Service d'Hématologie; Institut Paoli Calmette; Marseille France
| | - L. Voillat
- Service d'Hématologie; CH Chalon sur Saône; Chalon-sur-Saône France
| | - M. Parrens
- Service de Pathologie; CHU Bordeaux Haut Levèque; Pessac France
| | | | - V. Cacheux
- Service d'Hématologie; CHU de Clermont-Ferrand; Clermont Ferrand France
| | - C. Réguy
- Service d'Hématologie; CHU Grenoble; La Tronche France
| | - H. Tilly
- Service d'Hématologie; Centre Henri Becquerel; Rouen France
| | | | - P. Gaulard
- Département de Pathologie; Hôpital Henri Mondor; Créteil France
| | - L. de Leval
- Département de Pathologie; Centre Hospitalier Universitaire Vaudois; Lausanne Switzerland
| | - M. Delfau-Larrue
- Laboratoire d'immunologie; Université Paris Est, Hôpitaux Universitaires Henri Mondor; Créteil France
| | - C. Haioun
- Unité Hémopathies Lymphoïdes, INSERMU955; Université Paris Est, Hôpitaux Universitaires Henri Mondor; Créteil France
| |
Collapse
|
16
|
Kalakonda N, Cavallo F, Follows G, Goy A, Vermaat J, Casasnovas O, Lavee O, Maerevoet M, Zijlstra J, Bakshi S, Bouabdallah R, Choquet S, Gurion R, Hill B, Jaeger U, Sancho J, Schuster M, Thieblemont C, De la Cruz F, Egyed M, Mishra S, Offner F, Vassilakopoulos T, Warzocha K, Oluyadi A, McCarthy D, Ma X, Corona K, Shah J, Van Den Neste E, Canales M. A PHASE 2B STUDY OF SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL). Hematol Oncol 2019. [DOI: 10.1002/hon.31_2629] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- N. Kalakonda
- Molecular and Clinical Cancer Medicine; University of Liverpool; Liverpool United Kingdom
| | - F. Cavallo
- Molecular Biotechnology and Health Sciences; Aziena Ospedaliero - Universitaria Città della Salute e della Scienza di Torino; Turin Italy
| | - G. Follows
- Haematology; Cambridge University Hospitals NHS Foundation Trust Addenbrooke's Hospital; Cambridge United Kingdom
| | - A. Goy
- Oncology; Hackensack University Medical Center; Hackensack United States
| | - J. Vermaat
- Hematology; Leiden University Medical Center; Leiden Netherlands
| | | | - O. Lavee
- Hematology; St. Vincent's Hospital Sydney; Darlinghurst Australia
| | - M. Maerevoet
- Hematology; Service Hématologie, Institut Bordet; Bruxelles Belgium
| | - J. Zijlstra
- Hematology; Amsterdam UMC; Amsterdam Netherlands
| | - S. Bakshi
- Medical Oncology; Dr. B. R. A. Institute Rotary Cancer Hospital; New Delhi India
| | - R. Bouabdallah
- Oncology/Hematology; Institut Paoli-Calmettes; Marseille France
| | - S. Choquet
- Hematology; Hospital Pitie Salpetriere; Paris France
| | - R. Gurion
- Hematology; Rabin MC; Petah Tiqwa Israel
| | - B. Hill
- Hematology and Medical Oncology; Cleveland Clinic Main Campus; Cleveland United States
| | - U. Jaeger
- Medicine I; Medical University of Vienna; Vienna Austria
| | - J. Sancho
- Clinical Hematology; Hospital Germans Trias i Pujol; Barcelona Spain
| | - M. Schuster
- Medicine; Stony Brook University; Stony Brook United States
| | | | - F. De la Cruz
- Hematology; Hospital Universitario Virgen del Rocío; Sevilla Spain
| | - M. Egyed
- Hematology; Teaching Hospital Mór Kaposi; Kaposvár Hungary
| | - S. Mishra
- Medical Oncology; Institute of Medical Sciences & SUM Hospital; Bhubaneswar India
| | | | | | - K. Warzocha
- Hematology; Instytut Hematologii i Transfuzjologii; Warszawa Poland
| | - A. Oluyadi
- Clinical Development; Karyopharm Therapeutics Inc.; Newton United States
| | - D. McCarthy
- Clinical Operations; Karyopharm Therapeutics Inc.; Newton United States
| | - X. Ma
- Biostatistics; Karyopharm Therapeutics Inc.; Newton United States
| | - K. Corona
- Medical Affairs; Karyopharm Therapeutics Inc.; Newton United States
| | - J. Shah
- Clinical Development; Karyopharm Therapeutics Inc.; Newton United States
| | - E. Van Den Neste
- Hematology; Cliniques Universitaires Saint-Luc; Brussels Belgium
| | - M. Canales
- Medicine; Hospital Universitario La Paz; Madrid Spain
| |
Collapse
|
17
|
Cottereau A, Vercellino L, Casasnovas O, Tilly H, Feugier P, Fruchart C, Roulin L, Oberic L, Pica G, Ribrag V, Abraham J, Simon M, Gonzalez H, Bouabdallah R, Fitoussi O, Sebban C, Lopez A, Macro M, Sahnes L, Morschhauser F, Trotman J, Corront B, Choufi B, Snauwaert S, Godmer P, Copie-Bergman C, Briere J, Salles G, Gaulard P, Meignan M, Thieblemont C. HIGH TOTAL METABOLIC TUMOR VOLUME AT BASELINE ALLOWS TO DISCRIMINATE FOR SURVIVAL PATIENTS IN RESPONSE AFTER R-CHOP: AN ANCILLARY ANALYSIS OF THE REMARC STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.19_2629] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
| | - L. Vercellino
- Medecine Nucleaire; APHP, Saint-Louis Hospital; Paris France
| | | | - H. Tilly
- Hematology; Centre H. Becquerel; Rouen France
| | - P. Feugier
- Hematology; CHU Brabois - Nancy; Nancy France
| | | | - L. Roulin
- Hematology; APHP, Henri Mondor Hospital; Créteil France
| | - L. Oberic
- Hematology; CHU Toulouse; Toulouse France
| | - G. Pica
- Hematology; CHU Annecy; Annecy France
| | | | | | - M. Simon
- Hematology; CH Valenciennes; Valenciennes France
| | | | | | - O. Fitoussi
- Hematology; Hopital Bordeaux Nord; Bordeaux France
| | - C. Sebban
- Hematology; Centre L. Berard; Lyon France
| | - A. Lopez
- Hematology; IOB; Barcelona Spain
| | - M. Macro
- Hematology; CHU Caen; Caen France
| | - L. Sahnes
- Hematology; CH Perpignan; Perpignan France
| | | | - J. Trotman
- Hematology; Concord Hospital; Sydney Australia
| | | | - B. Choufi
- Hematology; CH Boulogne; Boulogne France
| | | | - P. Godmer
- Hematology; CH Vannes; Vannes France
| | | | - J. Briere
- Pathology; APHP, Saint-Louis Hospital; Paris France
| | - G. Salles
- Hematology; CHU Lyon; Pierre-Benite France
| | - P. Gaulard
- Pathology; APHP, Henri Mondor Hospital; Créteil France
| | - M. Meignan
- Medecine Nucleaire; APHP, Henri Mondor Hospital; Créteil France
| | | |
Collapse
|
18
|
Bossard C, Laghmari O, Le Bris Y, Bonnet A, Moreau A, El Alami Thomas W, Pavageau A, Guerzider P, Maisonneuve H, Ruminy P, Bene M, Casasnovas O, Canioni D, Thieblemont C, Petrella T, Jardin F, Salles G, Tilly H, Gaulard P, Haioun C, Brière J, Le Gouill S, Copie Bergman C, Molina T. REFINEMENT OF MUM1 EXPRESSION THRESHOLD FOR DOUBLE POSITIVE CD10+ MUM1+ DIFFUSE LARGE B CELL LYMPHOMA ALLOWS A BETTER CELL OF ORIGIN CLASSIFICATION FOR GCB SUBTYPE. Hematol Oncol 2019. [DOI: 10.1002/hon.11_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- C. Bossard
- Department of Pathology; University Hospital of Nantes; Nantes France
| | - O. Laghmari
- Department of Pathology; University Hospital of Nantes; Nantes France
| | - Y. Le Bris
- Department of Hematology Biology; University Hospital of Nantes; Nantes France
| | - A. Bonnet
- Department of Hematology; University Hospital of Nantes; Nantes France
| | - A. Moreau
- Department of Pathology; University Hospital of Nantes; Nantes France
| | | | - A. Pavageau
- Department of Pathology; Centre Hospitalier de la Roche sur Yon; La Roche sur Yon France
| | - P. Guerzider
- Department of Pathology; Centre Hospitalier de Saint Nazaire; Saint Nazaire France
| | - H. Maisonneuve
- Department of Hematology; Centre Hospitalier de la Roche sur Yon; La Roche sur Yon France
| | - P. Ruminy
- INSERM U918; Centre Henri Becquerel; Rouen France
| | - M. Bene
- Department of Hematology Biology; University Hospital of Nantes; Nantes France
| | - O. Casasnovas
- Department of Hematology; University Hospital; Dijon France
| | - D. Canioni
- Department of Pathology; Hopital Necker Enfants Malades; Paris France
| | - C. Thieblemont
- Hemato-oncology Department; Hopital Saint Louis; Paris France
| | - T. Petrella
- Department of Medical Oncology; Odette Cancer Center; Toronto Canada
| | - F. Jardin
- Department of Hematology; Centre Henri Becquerel; Rouen France
| | - G. Salles
- Department of Hematology; Hospice Civils de Lyon; Lyon France
| | - H. Tilly
- Department of Hematology; Centre Henri Becquerel; Rouen France
| | - P. Gaulard
- Department of Pathology; Groupe Hospitalier Henri Mondor; Creteil France
| | - C. Haioun
- Department of Hematology; Groupe Hospitalier Henri Mondor; Creteil France
| | - J. Brière
- Hemato-oncology Department; Hopital Saint Louis; Paris France
| | - S. Le Gouill
- Department of Hematology; University Hospital of Nantes; Nantes France
| | - C. Copie Bergman
- Department of Pathology; Groupe Hospitalier Henri Mondor; Creteil France
| | - T.J. Molina
- Department of Pathology; Hopital Necker Enfants Malades; Paris France
| |
Collapse
|
19
|
Sibon D, Quittet P, Borel C, Stamatoullas A, Franchi-Rezgui P, Ghesquieres H, Dulery R, Benbrahim O, Hammoud M, Durot E, De Guibert S, Coulibaly C, Casasnovas O, Bouabdallah R, Brice P. POOLED RESULTS OF THREE ANNUAL COHORTS FROM AN OBSERVATIONAL PROSPECTIVE STUDY DESCRIBING BRENTUXIMAB VEDOTIN USE IN ROUTINE PRACTICE IN FRANCE FOR HODGKIN LYMPHOMA: INTERIM ANALYSIS. Hematol Oncol 2019. [DOI: 10.1002/hon.170_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- D. Sibon
- Haematology; Hôpital Necker; Paris France
| | - P. Quittet
- Haematology; CHU Montpellier-Hop. ST Eloi; Montpellier France
| | - C. Borel
- Haematology; IUCT- Oncopole; Toulouse France
| | | | | | - H. Ghesquieres
- Haematology; Centre Hospitalier Lyon Sud; Pierre Bénite France
| | - R. Dulery
- Haematology; Hopital Saint Antoine; Paris France
| | | | - M. Hammoud
- Haematology; Hopital Henri Mondor; Créteil France
| | - E. Durot
- Haematology; Hopital Robert Debre; Reims France
| | | | | | | | | | - P. Brice
- Haematology; Hopital St Louis; Paris France
| |
Collapse
|
20
|
Delfau-Larue M, Boulland M, Feugier P, Maisonneuve H, Casasnovas O, Haioun C, Pica G, Lamy de la Chapelle T, Ysebaert L, Tilly H, Eisenmann J, Le Gouil S, Ribrag V, Jardel H, Glaisner S, Cartron G, Salles G, Xerri L, Fest T, Morschhauser F. RITUXIMAB PLUS LENALIDOMIDE IS AS EFFECTIVE AS IMMUNOCHEMOTHERAPY IN THE ERADICATION OF MOLECULAR DISEASE IN UNTREATED FOLLICULAR LYMPHOMA: RELEVANCE LYSA ANCILLARY STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.77_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M.H. Delfau-Larue
- Biological Hematology and Immunology Department; U955 Eq9, APHP, Groupe Hospitalier Mondor; Creteil France
| | - M.L. Boulland
- Hematobiology department; CHU Pontchaillou; Rennes France
| | - P. Feugier
- Service d'Hématologie; CHRU de Nancy; Vandoeuvre les Nancy France
| | - H. Maisonneuve
- Service d'Onco-Hématologie; CHD Vendée; La Roche-sur-Yon France
| | - O. Casasnovas
- Service d'Hématologie Clinique; CHU Le Bocage; Dijon France
| | - C. Haioun
- Unité Hémopathies Lymphoïdes; University hospital Mondor; Creteil France
| | - G.M. Pica
- Service Hématologie; CH Métropole Savoie; Chambéry France
| | | | - L. Ysebaert
- Service d'Hématologie; IUCT Oncopole; Toulouse France
| | - H. Tilly
- U1245 and Département d'Hématologie; Centre Henri Becquerel; Rouen France
| | - J.C. Eisenmann
- Département d'Hématologie; CH de Mulhouse; Hôp Emile Muller Mulhouse France
| | - S. Le Gouil
- Service d'Hématologie Clinique; CHU de Nantes - Hôtel Dieu; Nantes France
| | - V. Ribrag
- Hematology Department; Gustave Roussy Cancer Campus Grand Paris; Villejuif France
| | - H. Jardel
- Service Hématologie; Centre Hospitalier Bretagne-Atlantique; Vannes France
| | - S. Glaisner
- Service d'Hématologie; Centre René Huguenin; Saint-Cloud France
| | - G. Cartron
- Department of Hematology; CHU Montpellier; Montpellier France
| | - G. Salles
- Département d'Hématologie; Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud; Lyon France
| | - L. Xerri
- Departement de Bio-pathologie; Institut Paoli-Calmettes; Marseille France
| | - T. Fest
- Hematobiology department; CHU Pontchaillou; Rennes France
| | | |
Collapse
|
21
|
Rule S, Barreto W, Briones J, Carella A, Casasnovas O, Pocock C, Wendtner C, Zaja F, Robson S, Tschopp R, Dreyling M. EFFICACY AND SAFETY OF PROLONGED MAINTENANCE WITH SUBCUTANEOUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT NHL: RESULTS OF THE PHASE III MABCUTE STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.43_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- S. Rule
- Department of Haematology; Derriford Hospital and Plymouth University Medical School; Plymouth United Kingdom
| | - W.G. Barreto
- Hematology and Hemotherapy; Hemocentro Ribeirão Preto, University of São Paulo; São Paulo Brazil
| | - J. Briones
- Department of Hematology; Hospital de la Santa Creu i Sant Pau; Barcelona Spain
| | - A.M. Carella
- Division of Hematology and Stem Cell Transplantation Unit; L'Istituto di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliera Universitaria "San Martino" - Istituto Nazionale per la Ricerca sul Cancro; Genova Italy
| | - O. Casasnovas
- Service d'Hématologie Clinique; Centre Hospitalier Universitaire François Mitterand; Dijon France
| | - C. Pocock
- Department of Haematology; Kent & Canterbury Hospital; Canterbury United Kingdom
| | - C.M. Wendtner
- Department I of Internal Medicine; Klinikum Schwabing; Munich Germany
| | - F. Zaja
- SC Ematologia; Azienda Sanitaria Universitaria Integrata di Trieste; Trieste Italy
| | - S. Robson
- Product Development Medical Affairs; Biometrics, F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - R.R. Tschopp
- Product Development Medical Affairs; Oncology, F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - M. Dreyling
- Department of Medicine III; Klinikum der Universität München (LMU); Munich Germany
| |
Collapse
|
22
|
Berriolo-Riedinger A, Becker S, Casasnovas O, Vander Borght T, Édeline V. Role of FDG PET-CT in the treatment management of Hodgkin lymphoma. Cancer Radiother 2018; 22:393-400. [PMID: 30033076 DOI: 10.1016/j.canrad.2018.06.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2018] [Accepted: 06/21/2018] [Indexed: 12/29/2022]
Abstract
Fluorodeoxyglucose (FDG) positons emission tomography (PET)-computed tomography (CT) is used in many ways at baseline and during the treatment of patients with Hodgkin lymphoma. Many properties of the technique are used in the different steps of patient's management. Initial staging with PET-CT is more accurate than conventional imaging and PET-CT also became the gold standard imaging at the end of treatment with a negative PET-CT mandatory for reaching a complete remission. Early assessment of response by PET-CT is one of the most powerful prognostic factors for progression-free survival of patients with localized and advanced stages and allows guiding treatment. Conversely, previous studies showed that there is no role of FDG PET-CT for the patient's follow-up.
Collapse
Affiliation(s)
- A Berriolo-Riedinger
- Department of Nuclear Medicine, centre Georges-François-Leclerc, 1, rue du Pr-Marion, 21000 Dijon, France
| | - S Becker
- Department of Nuclear Medicine, centre Henri-Becquerel, 1, rue d'Amiens, 76038 Rouen, France
| | - O Casasnovas
- Department of Hematology, CHU F.-Mitterrand, 21000 Dijon, France; Inserm, UMR 1231, 21000 Dijon, France
| | - T Vander Borght
- Department Nuclear Medicine, CHU UCL Namur, site de Godinne, rue Dr-Gaston-Thérasse 1, 5530 Yvoir, Belgium; Namur Research Institute in Life Sciences (Narilis), rue de Bruxelles 61, 5000 Namur, Belgium
| | - V Édeline
- Department of Nuclear Medicine, hôpital René-Huguenin, institut Curie, 35, rue Dailly, 92210 Saint-Cloud, France.
| |
Collapse
|
23
|
Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, Damaj G, Gastinne T, Ribrag V, Feugier P, Casasnovas O, Zerazhi H, Haioun C, Maisonneuve H, Van Den Neste E, Tournilhac O, Le Dû K, Morschhauser F, Cartron G, Fornecker L, Salles G, Tilly H, Lamy T, Gressin R, Hermine O. Rituximab maintenance after autologous stem-cell transplantation in patients with mantle cell lymphoma, final result of the LyMA trial conducted on behalf the LYSA group. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_74] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
| | - C. Thieblemont
- Hemato-Oncologie, APHP, Hôpital Saint-Louis; Paris France
| | - L. Oberic
- Hématologie, IUCT Oncopole; Toulouse France
| | - A. Moreau
- Hématologie, CHU De Nantes; Nantes France
| | | | | | - G. Damaj
- Hématologie, CHU Caen; Caen France
| | | | | | | | | | | | - C. Haioun
- hématologie, CHU Creteil; Creteil France
| | | | | | - O. Tournilhac
- Hématologie, CHU Clermont-Ferrand; Clermont-Ferrand France
| | - K. Le Dû
- Hématologie, Clinique Victor Hugo; Le Mans France
| | | | - G. Cartron
- hématologie, CHU Montpellier; Montpellier France
| | | | - G. Salles
- Hématologie, AP-HL Lyon; Lyon France
| | - H. Tilly
- hématologie, Centre Becquerel; Rouen France
| | - T. Lamy
- Hématologie, CHU Rennes; Rennes France
| | - R. Gressin
- Hématologie, CHU Grenoble; Grenoble France
| | - O. Hermine
- Hématologie, AP-HP Necker Paris; Paris France
| |
Collapse
|
24
|
Le Gouill S, Morschhauser F, Bouabdallah K, Cartron G, Casasnovas O, Davies A, Chiron D, Rule S. OBINUTUZUMAB PLUS IBRUTINIB IN RELAPSE/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS: FIRST RESULTS OF THE OASIS PHASE I TRIAL. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_73] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
| | | | | | - G. Cartron
- Hématologie, Chu Montpellier; Montpellier France
| | | | - A. Davies
- Hematology; Southampton University Hospital; Southampton UK
| | | | - S. Rule
- Hematology; Plymouth Medical University; Plymouth UK
| |
Collapse
|
25
|
Sesques P, Golfier C, Boursier J, Bachy E, Traverse-Glehen A, Le Gouill S, Casasnovas O, Ghesquieres H, Salles G. CHARACTERISTICS AND OUTCOMES OF RELAPSED FOLLICULAR LYMPHOMA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN THE RITUXIMAB ERA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_84] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- P. Sesques
- Department of Hematology, CHU Lyon Sud; Pierre Benite France
| | - C. Golfier
- Department of Hematology, CHU Dijon; Dijon France
| | - J. Boursier
- Department Of Hematology, CHU Nantes; Nantes France
| | - E. Bachy
- Department of Hematology, CHU Lyon Sud; Pierre Benite France
| | | | - S. Le Gouill
- Department Of Hematology, CHU Nantes; Nantes France
| | | | - H. Ghesquieres
- Department of Hematology, CHU Lyon Sud; Pierre Benite France
| | - G. Salles
- Department of Hematology, CHU Lyon Sud; Pierre Benite France
| |
Collapse
|
26
|
Canioni D, Brice P, Bologna S, Voillat L, Gabarre J, Casasnovas O, Devidas A, Coiffier B, Aoudjhane A, Audouy B, Andre M, Fortpied C, Carde P, Mounier N, Briere J. PROGNOSTIC VALUE OF IMMUNOHISTOCHEMICAL MARKERS IN STAGE III/IV CLASSICAL HODGKIN LYMPHOMA TREATED FRONTLINE IN THE LYSA EORTC 20012 RANDOMIZED PROTOCOL. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- D. Canioni
- Pathology Department; Hopital Necker; Paris France
| | - P. Brice
- Hematology Department; Hopital Saint-Louis; France
| | - S. Bologna
- Meurte-Moselle; Centre d'Oncologie de Gentilly, Essey-les Nancy; France
| | - L. Voillat
- Hematology Department; Centre Hospitalier de Chalon sur Saône, Chalon sur Saone; France
| | - J. Gabarre
- Hematology Department; Hopital Pitié-Salpétrière; France
| | | | - A. Devidas
- Hematology Department; CH de Corbeil-Essones; Corbeil- Essones France
| | - B. Coiffier
- Hematology Department; Hospices Civils de Lyon; Pierre Bénite France
| | - A. Aoudjhane
- Hematology Department; Hopital Saint-Antoine; France
| | - B. Audouy
- Hematology Department; CH de Colmar; Colmar France
| | - M. Andre
- Hematology Department; CH de Mont Godinne; Yvoir Belgium
| | | | - P. Carde
- Hematology Department; Hopital Américain, Neuillyè-sur-Seine; France
| | - N. Mounier
- Hematology Department; Hopital de l'Archet; Nice France
| | - J. Briere
- Pathology Department; Hopital Necker; Paris France
| |
Collapse
|
27
|
Bröckelmann P, Müller H, Casasnovas O, Hutchings M, von Tresckow B, Jürgens M, McCall S, Morschhauser F, Fuchs M, Borchmann P, Moskowitz C, Engert A. Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma. Ann Oncol 2017; 28:1352-1358. [DOI: 10.1093/annonc/mdx072] [Citation(s) in RCA: 62] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
28
|
Laurent C, Casasnovas O, Martin L, Chauchet A, Ghesquieres H, Aussedat G, Fornecker LM, Bologna S, Borot S, Laurent K, Bouillet B, Verges B, Petit JM. Adrenal lymphoma: presentation, management and prognosis. QJM 2017; 110:103-109. [PMID: 27795295 DOI: 10.1093/qjmed/hcw174] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/21/2016] [Indexed: 12/17/2022] Open
Abstract
AIM This study aimed to identify the clinical, radiological and prognostic features of primary adrenal lymphoma (PAL) in order to diagnose the disease more accurately. MATERIALS AND METHODS A retrospective multi-centre study was conducted on the clinical, biological and radiological features as well as the treatment and overall survival outcomes in PAL. RESULTS Between 1994 and 2014, 28 patients from five regions of eastern France were diagnosed with primary adrenal lymphoma. The revealing symptoms were a worsening general state (77%), weight loss (77%) and abdominal pain (42%). Biological features of PAL were almost omnipresent: increased LDH, β2 microglobulin, CRP or ferritinaemia levels. The PAL was bilateral in 20 cases (71%), adrenal insufficiency was searched for in 11 patients and found in eight (73%). CT scans showed masses of various sizes measuring up to 180 mm. On MRI, the lesions were hypointense in T1 and hyperintense in T2. When done, positron emission tomography with fluorodeoxyglucose (FDG-PET) showed locations not seen on the CT and revealed extra-adrenal locations in 70% of examinations. Adrenalectomy brought no benefit. The overall survival rate was poor (61.9% at 2 years) despite polychemotherapy. CONCLUSION The clinical presentation of PAL comprised major general symptoms. Adrenal insufficiency was very common in patients with bilateral involvement but was not systematically tested. PET was an efficient examination to visualize extra-adrenal locations. The preliminary results of MRI to distinguish between PAL and adrenocortical carcinoma should be confirmed. Further studies are needed to establish an optimal strategy for the management of these primary adrenal lymphomas.
Collapse
Affiliation(s)
- C Laurent
- From the Department of Endocrinology, University Hospital of Dijon, Dijon, France
| | - O Casasnovas
- Department of Hematology, University Hospital of Dijon, Dijon, France
| | - L Martin
- Department of Pathology, University Hospital of Dijon, Dijon, France
| | - A Chauchet
- Department of Hematology, University Hospital of Besancon, Besancon, France
| | - H Ghesquieres
- Department of Hematology, Centre Leon Berard, University Hospital of Lyon, Lyon, France
| | - G Aussedat
- Department of Hematology, Centre Leon Berard, University Hospital of Lyon, Lyon, France
| | - L M Fornecker
- Department of Hematology, University Hospital of Strasbourg, Strasbourg, France
| | - S Bologna
- Department of Hematology, University Hospital of Nancy, Nancy, France
| | - S Borot
- Department of Endocrinology, University Hospital of Besancon, Besancon, France
| | - K Laurent
- University of Science and Technology of Nancy, Nancy, France
| | - B Bouillet
- From the Department of Endocrinology, University Hospital of Dijon, Dijon, France
| | - B Verges
- From the Department of Endocrinology, University Hospital of Dijon, Dijon, France
| | - J-M Petit
- From the Department of Endocrinology, University Hospital of Dijon, Dijon, France
| |
Collapse
|
29
|
Ghez D, Fortpied C, Mounier N, Carde P, Perrot A, Khaled H, Amorim S, Ramadan S, Bras FL, Erlanson M, Herbaux C, Marolleau JP, Nicolas-Virelezier E, Casasnovas O, Stamatoullas-Bastard A, Fermé C. First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin's lymphoma. Bone Marrow Transplant 2016; 52:310-312. [PMID: 27892946 DOI: 10.1038/bmt.2016.271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- D Ghez
- Department of Hematology, Gustave Roussy, Villejuif, France
| | | | - N Mounier
- Department of Onco-Hematology, CHU l'Archet, Nice, France
| | - P Carde
- Department of Hematology, Gustave Roussy, Villejuif, France
| | - A Perrot
- Department of Hematology, CHU Nancy-Brabois, Vandoeuvre Les Nancy, France
| | - H Khaled
- Department of Medical Oncology, National Cancer Institute, Cairo, Egypt
| | - S Amorim
- Department of Oncology and Hematology, Hopital Saint-Louis APHP, Université Paris Diderot, Paris, France
| | - S Ramadan
- EORTC Headquarters, Brussels, Belgium
| | - F L Bras
- Unité Hémopathies Lymphoïdes, Hôpital Henri Mondor, Creteil, France
| | - M Erlanson
- Department of Oncology, Umea Universitet, Umea, Sweden
| | - C Herbaux
- Department of Clinical Hematology, Hôpital Claude Huriez, Université de Lille 2, Lille, France
| | - J-P Marolleau
- Department of Hematology, CHU Amiens, Université Picardie Jules Verne, Amiens, France
| | | | - O Casasnovas
- Department of Hematology, CHU Dijon, Dijon, France
| | | | - C Fermé
- Department of Hematology, Gustave Roussy, Villejuif, France
| |
Collapse
|
30
|
Houot R, Soussain C, Tilly H, Haioun C, Thieblemont C, Casasnovas O, Bouabdallah K, Morschhauser F, Le Gouill S, Salles G, Hoang-Xuan K, Choquet S, Marchand T, Laurent C, Pangault C, Lamy T. Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA. Ann Oncol 2016; 27:1349-50. [DOI: 10.1093/annonc/mdw138] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
31
|
Cottereau A, Becker S, Broussais F, Casasnovas O, Kanoun S, Roques M, Charrier N, Bertrand S, Delarue R, Bonnet C, Hustinx R, Gaulard P, de Leval L, Vera P, Itti E, Mounier N, Haioun C, Tilly H, Meignan M. Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL). Ann Oncol 2016; 27:719-24. [DOI: 10.1093/annonc/mdw011] [Citation(s) in RCA: 72] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2015] [Accepted: 12/24/2015] [Indexed: 12/13/2022] Open
|
32
|
Mounier N, Brice P, Bologna S, Briere J, Gaillard I, Heczko M, Gabarre J, Casasnovas O, Jaubert J, Colin P, Delmer A, Devidas A, Bachy E, Nicolas-Virelizier E, Aoudjhane A, Humbrecht C, Andre M, Carde P. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low-risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial. Ann Oncol 2014; 25:1622-8. [DOI: 10.1093/annonc/mdu189] [Citation(s) in RCA: 79] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
33
|
van der Kaaij M, van Echten-Arends J, Heutte N, Meijnders P, Abeilard-Lemoisson E, Spina M, Moser E, Allgeier A, Meulemans B, Lugtenburg P, Aleman B, Noordijk E, Fermé C, Thomas J, Stamatoullas A, Fruchart C, Eghbali H, Brice P, Smit W, Sebban C, Doorduijn J, Roesink J, Gaillard I, Coiffier B, Lybeert M, Casasnovas O, André M, Raemaekers J, Henry-Amar M, Kluin-Nelemans J. Cryopreservation, semen use and the likelihood of fatherhood in male Hodgkin lymphoma survivors: an EORTC-GELA Lymphoma Group cohort study. Hum Reprod 2013; 29:525-33. [DOI: 10.1093/humrep/det430] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Ketterer N, Coiffier B, Thieblemont C, Fermé C, Brière J, Casasnovas O, Bologna S, Christian B, Connerotte T, Récher C, Bordessoule D, Fruchart C, Delarue R, Bonnet C, Morschhauser F, Anglaret B, Soussain C, Fabiani B, Tilly H, Haioun C. Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B). Ann Oncol 2012; 24:1032-7. [PMID: 23235801 DOI: 10.1093/annonc/mds600] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
BACKGROUND The superiority of a chemotherapy with doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone (ACVBP) in comparison with cyclophosphamide, doxorubicin, vincristin and prednisone plus radiotherapy for young patients with localized diffuse large B-cell lymphoma (DLBCL) was previously demonstrated. We report the results of a trial which evaluates the role of rituximab combined with ACVBP (R-ACVBP) in these patients. PATIENTS AND METHODS Untreated patients younger than 66 years with stage I or II DLBCL and no adverse prognostic factors of the age-adjusted International Prognostic Index were randomly assigned to receive three cycles of ACVBP plus sequential consolidation with or without the addition of four infusions of rituximab. RESULTS A total of 223 patients were randomly allocated to the study, 110 in the R-ACVBP group and 113 in the ACVBP group. After a median follow-up of 43 months, our 3-year estimate of event-free survival was 93% in the R-ACVBP group and 82% in the ACVBP group (P = 0.0487). Three-year estimate of progression-free survival was increased in the R-ACVBP group (95% versus 83%, P = 0.0205). Overall survival did not differ between the two groups with a 3-year estimates of 98% and 97%, respectively (P = 0.686). CONCLUSION In young patients with low-risk localized DLBCL, rituximab combined with three cycles of ACVBP plus consolidation is significantly superior to ACVBP plus consolidation alone.
Collapse
Affiliation(s)
- N Ketterer
- Department of Oncology, University Hospital, Lausanne, Switzerland.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Tilly H, Morschhauser F, Salles GA, Casasnovas O, Feugier P, Molina TJ, Haioun C, Coiffier B. A phase I study of escalating doses of lenalidomide combined with R-CHOP (R2-CHOP) for front-line treatment of B-cell lymphomas. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.tps297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
36
|
Joly B, Plonquet A, Grare M, Delfau-Larue M, Delarue R, Delmer A, Casasnovas O, Gisselbrecht C, Gaulard P, Haioun C. Rituximab in combination with CHOP regimen in angioimmunoblastic T-cell lymphoma: Results of the phase II RAIL trial—A prospective study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.8049] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
37
|
EL Gnaoui T, Tilly H, Mounier N, Gisselbrecht C, Sebban C, Casasnovas O, Delarue R, Petrella T, Canioni D, Haioun C. Rituximab plus gemcitabine and oxaliplatine (R-GemOx) in refractory/relapsed patients with diffuse large B-cell lymphoma (DLBCL) who are not candidates for high-dose therapy (HDT): A GELA study. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.8011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
38
|
Ghesquières H, Ferlay C, Sebban C, Perol D, Bosly A, Casasnovas O, Reman O, Coiffier B, Tilly H, Morel P, Van den Neste E, Colin P, Haioun C, Biron P, Blay JY. Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Ann Oncol 2010; 21:842-850. [DOI: 10.1093/annonc/mdp529] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
39
|
Casasnovas O, Thieblemont C, Rossi J, Sicard H, Ingoure S, Audibert F, de Micheaux SL, Laurent G. 9200 Phase II study of IPH1101 (with low dose of IL-2) in combination with rituximab re-treatment in patients with follicular lymphoma. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71891-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
40
|
Mounier N, Gisselbrecht C, Fitoussi O, Belhadj K, Feugier P, Coiffier B, Tilly H, Casasnovas O, Fermé C, Briere J, Haioun C. Benefit of rituximab combined to ACVBP (R-ACVBP) over ACVBP in 209 poor- risk BDLC NHL patients treated with up-front consolidative autotransplantation: A GELA phase II trial (LNH 2003–3). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.8507] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8507 Background: Rituximab (R) combined with CHOP improves survival in DLBCL pts. More intensive regimen followed by auto transplantation have been used in patients < 60y with 2–3 adverse age-adjusted International-Prognostic-Index (aa-IPI) factors, providing a 5y OS of 65% (CI 60–68%), (Haioun LNH 98–3B, ASCO 2007). The objective of the present study was to assess whether or not combining R (375 mg/m2) to the dose intense ACVBP (doxorubicin 75 mg/m2 d1, cyclophosphamide 1,200 mg/m2 d1, vindesine 2 mg/m2 and bleomycin 10 mg d1 and d5, prednisone 60 mg/m2 d1-d5) also translates into a survival benefit. Methods: From 01/2004 to 12/2005, 209 DLCBL pts < 60y with DLBCL and aaIPI 2 or 3 received 4 cycles of R-ACVBP every 15 days. CR and PR pts received a consolidative BEAM and peripheral blood stem cell rescue (LNH2003–3 trial, # NCT00144807 ). Median age was 49 years, 22 % of patients presented with aa-IPI 3, 58% with IPI 3–5 (93% with elevated LDH and 54 % with extranodal sites >1). CR rate after induction was 61%, PR rate 24% leading to an overall response rate of 84% (176 pts). Collection failure was observed in 18 pts (10%). 155 pts received auto transplantation, representing 75% of the study population. Results: With a median follow-up of 27 months, according to the updated IWC 2007, 3y PFS and OS were estimated at 76% (CI 69–81%) and 81% (CI 75–86%), respectively. A case-controlled study was performed by matching the present R-ACVBP population with ACVBP patients selected from the LNH-98–3 trial. Patients were fully matched (1:1) on histology, aa-IPI score, gender, age and follow-up duration. 3y PFS was higher in R-ACVBP than in ACVBP patients: 75% (CI 67–81%) vs 58% (CI 50–65%), p=0.0003. 3y OS were estimated at 78% (CI 71–84%) vs 67% (CI 58–74%), p=0.05. The gain in 3y OS was significant in patients who received auto transplantation: 89% (CI 81–93%) vs 77% (CI 67–84%), p=0.02. Conclusions: These results with R-ACVBP induction and consolidative auto-transplantation suggest a major survival benefit which needs confirmatory prospective study. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- N. Mounier
- CHU L'Archet, Nice, France; GELA, Paris, France
| | | | - O. Fitoussi
- CHU L'Archet, Nice, France; GELA, Paris, France
| | - K. Belhadj
- CHU L'Archet, Nice, France; GELA, Paris, France
| | - P. Feugier
- CHU L'Archet, Nice, France; GELA, Paris, France
| | - B. Coiffier
- CHU L'Archet, Nice, France; GELA, Paris, France
| | - H. Tilly
- CHU L'Archet, Nice, France; GELA, Paris, France
| | | | - C. Fermé
- CHU L'Archet, Nice, France; GELA, Paris, France
| | - J. Briere
- CHU L'Archet, Nice, France; GELA, Paris, France
| | - C. Haioun
- CHU L'Archet, Nice, France; GELA, Paris, France
| |
Collapse
|
41
|
Régis A, Ben Salem D, Lambert A, Couaillier JF, Casasnovas O, Piard F, Krausé D. [Concomitant pulmonary Langerhans cell histiocytosis and malignant lymphoma: report of two cases]. ACTA ACUST UNITED AC 2009; 90:66-8. [PMID: 19182717 DOI: 10.1016/s0221-0363(09)70081-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
42
|
Lacombe F, Arnoulet C, Maynadié M, Lippert E, Luquet I, Pigneux A, Vey N, Casasnovas O, Witz F, Béné MC. Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study. Leukemia 2008; 23:350-7. [DOI: 10.1038/leu.2008.296] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
43
|
You B, Michallet A, Salles G, Casasnovas O, Tilly H, Ribrag V, Sebban C, Falandry C, Tranchand B, Freyer G. Major dispersion in etoposide systemic exposure in malignant lymphoma patients receiving BEAM high dose chemotherapy followed by ABMT: A multicentre study of the Groupe d’Etudes des Lymphomes de l’Adulte (GELA). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.8537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
44
|
Plonquet A, Haioun C, Jais JP, Debard AL, Salles G, Bene MC, Feugier P, Rabian C, Casasnovas O, Labalette M, Kuhlein E, Farcet JP, Emile JF, Gisselbrecht C, Delfau-Larue MH. Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma. Ann Oncol 2007; 18:1209-15. [PMID: 17496307 DOI: 10.1093/annonc/mdm110] [Citation(s) in RCA: 70] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Lymphocytopenia is a prognostic factor in Hodgkin's disease. In diffuse large B-cell lymphoma (DLBCL), data are much less established, in spite of numerous reports on immune system-lymphoma interactions. This study addresses the prognostic value of blood lymphocyte subsets at diagnosis in DLBCL. PATIENTS AND METHODS Absolute values of blood lymphocyte subsets and monocytes were prospectively determined by flow cytometry in 140 patients with 2 or 3 adverse age-adjusted International Prognostic Index (aaIPI) factors included in a Groupe d'Etude des Lymphomes de l'Adulte protocol (LNH98B3). Absolute cell counts at diagnosis and aaIPI were evaluated with regard to clinical outcome. RESULTS Low median cell counts of 337, 211, and 104/mul were evidenced for the CD4+, CD8+ T, and natural killer (NK) cells, respectively. In univariate analysis, only NK cell count [odds ratio (OR) = 1.81 (1.27, 2.57), P = 0.001] and aaIPI [OR = 2.29 (0.95, 5.45), P = 0.06] were associated with induction treatment response. Low NK cell count [Hazard ratio (HR) = 1.27 (1.06, 1.52), P = 0.01] and aaIPI 3 [HR = 1.95 (1.20, 3.16), P = 0.01] were also associated with a shorter event free survival (EFS). In multivariate analysis, NK cell count was associated with response [OR = 1.77 (1.24, 2.54), P = 0.002] and EFS [HR = 1.25 (1.04, 1.50) P = 0.02] independently of aaIPI. CONCLUSIONS This study shows an association between circulating NK cell number and clinical outcome in DLBCL, possibly important in the context of the broadening use of rituximab, a likely NK-dependent therapy.
Collapse
MESH Headings
- Adult
- Antibodies, Monoclonal/administration & dosage
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Combined Chemotherapy Protocols/administration & dosage
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- B-Lymphocytes/cytology
- Bleomycin/administration & dosage
- CD4-Positive T-Lymphocytes/cytology
- CD8-Positive T-Lymphocytes/cytology
- Cell Count
- Cyclophosphamide/administration & dosage
- Doxorubicin/administration & dosage
- Etoposide/administration & dosage
- Female
- Flow Cytometry
- Humans
- Immunophenotyping
- Kaplan-Meier Estimate
- Killer Cells, Natural/cytology
- Lymphoma, Large B-Cell, Diffuse/drug therapy
- Lymphoma, Large B-Cell, Diffuse/immunology
- Lymphoma, Large B-Cell, Diffuse/mortality
- Lymphopenia
- Male
- Middle Aged
- Monocytes/cytology
- Peripheral Blood Stem Cell Transplantation
- Rituximab
- Treatment Outcome
- Vincristine/administration & dosage
Collapse
Affiliation(s)
- A Plonquet
- Service d'Immunologie Biologique, Institut National de la Santé et de la Recherche Médicale, U617, Créteil, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Foussard C, Mounier N, Van Hoof A, Delwail V, Casasnovas O, Deconinck E, Tilly H, Fitoussi O, Gressin R, Salles G, Gela-Goelams. Update of the FL2000 randomized trial combining rituximab to CHVP-Interferon in follicular lymphoma (FL) patients (pts). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7508] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7508 Background: The GELA-GOELAMS FL2000 trial investigated the role of rituximab in the first line treatment of FL pts. Methods: This prospective randomized study compared the CHVP regimen (12 courses) +18 months α2b-IFN (CHVP-I) to 6 CHVP courses combined with 6 rituximab infusions + 18 months IFN (R-CHVP-I). The primary endpoint was event-free survival (EFS). Inclusion criteria consisted in untreated stage II-IV FL pts; 18–75 years old; with a high tumor burden defined by at least one of the following criteria: B symptoms, ECOG PS>1, LDH>normal value, β2-microglobulin ≥3 mg/L, largest tumor ≥7 cm, 3 distinct nodes ≥3 cm, serous effusion, compression or symptomatic spleen enlargement. Results: From 05/00 until 05/02, 358 eligible pts were randomized (CHVP-I 183 pts and R-CHVP-I 175 pts) with the following characteristics: M/F = 1; median age = 60 years [25–75]; ECOG > 1 = 8%; B symptoms = 27%; AA stage > II = 87%; bone marrow involvement = 58%; β2-m ≥3 mg/L = 31%; LDH > N = 37%; Hb <12 g/dL = 18%; FLIPI score ≥3 in 57% of the pts. The first analysis [ASH 2004] showed a significant better treatment response in R-CHVP-I as compared to CHVP-I and a improvement of event free survival (EFS) in the R-CHVP-I arm (Log-Rang, P = .003). As initially planned, a second analysis on all pts has now been performed with a median follow-up of 3½ years, all pts with data >01/01/05. The median EFS for the whole population has not yet been reached. In the CHVP-I arm, median EFS was 3 years and 46% of the pts are event-free at 42 months (mo.). In contrast, the median has not been reached in the R-CHVP-I arm and the EFS is 67% at 42 mo. (P < .0001). This improvement in EFS was found both in the 150 pts with a low or intermediate FLIPI score (P = .019) and in those (n = 201) with a high score (P = .0005). When considering the 230 pts responders at the end of 18 mo. of therapy, 42 mo. EFS is 62% in CHVP-I arm versus 81% in R-CHVP-I arm (P = .002). Finally, the overall survival at 42 mo. of patients in the CHVP-I arm is of 84% versus to 91% in the R-CHVP-I arm (P = .029) with a reduction of death risk by approximately 2 (RR = 0.55). Conclusions: These results demonstrate that rituximab combined with CHVP-I has a durable benefit, in all FLIPI risk groups, allows to reduce the duration of chemotherapy and improves overall survival in high-tumor burden FL pts. [Table: see text]
Collapse
Affiliation(s)
- C. Foussard
- CHU, Angers, France; Hôpital Saint-Louis, Paris, France; AZ St. Jan, Brugges, Belgium; CHU, Poitier, France; CHU, Dijon, France; CHU, Besançon, France; Centre Henri Becquerel, Rouen, France; Polyclinique Nord, Bordeaux, France; CHU, Grenoble, France; Hospices Civils de Lyon, Lyon, France
| | - N. Mounier
- CHU, Angers, France; Hôpital Saint-Louis, Paris, France; AZ St. Jan, Brugges, Belgium; CHU, Poitier, France; CHU, Dijon, France; CHU, Besançon, France; Centre Henri Becquerel, Rouen, France; Polyclinique Nord, Bordeaux, France; CHU, Grenoble, France; Hospices Civils de Lyon, Lyon, France
| | - A. Van Hoof
- CHU, Angers, France; Hôpital Saint-Louis, Paris, France; AZ St. Jan, Brugges, Belgium; CHU, Poitier, France; CHU, Dijon, France; CHU, Besançon, France; Centre Henri Becquerel, Rouen, France; Polyclinique Nord, Bordeaux, France; CHU, Grenoble, France; Hospices Civils de Lyon, Lyon, France
| | - V. Delwail
- CHU, Angers, France; Hôpital Saint-Louis, Paris, France; AZ St. Jan, Brugges, Belgium; CHU, Poitier, France; CHU, Dijon, France; CHU, Besançon, France; Centre Henri Becquerel, Rouen, France; Polyclinique Nord, Bordeaux, France; CHU, Grenoble, France; Hospices Civils de Lyon, Lyon, France
| | - O. Casasnovas
- CHU, Angers, France; Hôpital Saint-Louis, Paris, France; AZ St. Jan, Brugges, Belgium; CHU, Poitier, France; CHU, Dijon, France; CHU, Besançon, France; Centre Henri Becquerel, Rouen, France; Polyclinique Nord, Bordeaux, France; CHU, Grenoble, France; Hospices Civils de Lyon, Lyon, France
| | - E. Deconinck
- CHU, Angers, France; Hôpital Saint-Louis, Paris, France; AZ St. Jan, Brugges, Belgium; CHU, Poitier, France; CHU, Dijon, France; CHU, Besançon, France; Centre Henri Becquerel, Rouen, France; Polyclinique Nord, Bordeaux, France; CHU, Grenoble, France; Hospices Civils de Lyon, Lyon, France
| | - H. Tilly
- CHU, Angers, France; Hôpital Saint-Louis, Paris, France; AZ St. Jan, Brugges, Belgium; CHU, Poitier, France; CHU, Dijon, France; CHU, Besançon, France; Centre Henri Becquerel, Rouen, France; Polyclinique Nord, Bordeaux, France; CHU, Grenoble, France; Hospices Civils de Lyon, Lyon, France
| | - O. Fitoussi
- CHU, Angers, France; Hôpital Saint-Louis, Paris, France; AZ St. Jan, Brugges, Belgium; CHU, Poitier, France; CHU, Dijon, France; CHU, Besançon, France; Centre Henri Becquerel, Rouen, France; Polyclinique Nord, Bordeaux, France; CHU, Grenoble, France; Hospices Civils de Lyon, Lyon, France
| | - R. Gressin
- CHU, Angers, France; Hôpital Saint-Louis, Paris, France; AZ St. Jan, Brugges, Belgium; CHU, Poitier, France; CHU, Dijon, France; CHU, Besançon, France; Centre Henri Becquerel, Rouen, France; Polyclinique Nord, Bordeaux, France; CHU, Grenoble, France; Hospices Civils de Lyon, Lyon, France
| | - G. Salles
- CHU, Angers, France; Hôpital Saint-Louis, Paris, France; AZ St. Jan, Brugges, Belgium; CHU, Poitier, France; CHU, Dijon, France; CHU, Besançon, France; Centre Henri Becquerel, Rouen, France; Polyclinique Nord, Bordeaux, France; CHU, Grenoble, France; Hospices Civils de Lyon, Lyon, France
| | - Gela-Goelams
- CHU, Angers, France; Hôpital Saint-Louis, Paris, France; AZ St. Jan, Brugges, Belgium; CHU, Poitier, France; CHU, Dijon, France; CHU, Besançon, France; Centre Henri Becquerel, Rouen, France; Polyclinique Nord, Bordeaux, France; CHU, Grenoble, France; Hospices Civils de Lyon, Lyon, France
| |
Collapse
|
46
|
Camilleri-Broët S, Mounier N, Delmer A, Brière J, Casasnovas O, Cassard L, Gaulard P, Christian B, Coiffier B, Sautès-Fridman C. FcγRIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP). Leukemia 2004; 18:2038-40. [PMID: 15470484 DOI: 10.1038/sj.leu.2403536] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
47
|
Delarue R, Haioun C, Brice P, Delmer A, Ribrag V, Van Hoof A, Casasnovas O, Tilly H, Salles G, Hermine O. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): A pilot study from the GELA. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.6529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- R. Delarue
- Hopital Necker, Paris, France; Hopital Henri Mondor, Creteil, France; Hopital Saint Louis, Paris, France; Hopital Hotel Dieu, Paris, France; Institut Gustave Roussy, Villejuif, France; AZ Saint Jan, Brugge, Belgium; CHU Dijon, Dijon, France; Centre Henri Becquerel, Rouen, France; CH Lyon Sud, Pierre Benite, France
| | - C. Haioun
- Hopital Necker, Paris, France; Hopital Henri Mondor, Creteil, France; Hopital Saint Louis, Paris, France; Hopital Hotel Dieu, Paris, France; Institut Gustave Roussy, Villejuif, France; AZ Saint Jan, Brugge, Belgium; CHU Dijon, Dijon, France; Centre Henri Becquerel, Rouen, France; CH Lyon Sud, Pierre Benite, France
| | - P. Brice
- Hopital Necker, Paris, France; Hopital Henri Mondor, Creteil, France; Hopital Saint Louis, Paris, France; Hopital Hotel Dieu, Paris, France; Institut Gustave Roussy, Villejuif, France; AZ Saint Jan, Brugge, Belgium; CHU Dijon, Dijon, France; Centre Henri Becquerel, Rouen, France; CH Lyon Sud, Pierre Benite, France
| | - A. Delmer
- Hopital Necker, Paris, France; Hopital Henri Mondor, Creteil, France; Hopital Saint Louis, Paris, France; Hopital Hotel Dieu, Paris, France; Institut Gustave Roussy, Villejuif, France; AZ Saint Jan, Brugge, Belgium; CHU Dijon, Dijon, France; Centre Henri Becquerel, Rouen, France; CH Lyon Sud, Pierre Benite, France
| | - V. Ribrag
- Hopital Necker, Paris, France; Hopital Henri Mondor, Creteil, France; Hopital Saint Louis, Paris, France; Hopital Hotel Dieu, Paris, France; Institut Gustave Roussy, Villejuif, France; AZ Saint Jan, Brugge, Belgium; CHU Dijon, Dijon, France; Centre Henri Becquerel, Rouen, France; CH Lyon Sud, Pierre Benite, France
| | - A. Van Hoof
- Hopital Necker, Paris, France; Hopital Henri Mondor, Creteil, France; Hopital Saint Louis, Paris, France; Hopital Hotel Dieu, Paris, France; Institut Gustave Roussy, Villejuif, France; AZ Saint Jan, Brugge, Belgium; CHU Dijon, Dijon, France; Centre Henri Becquerel, Rouen, France; CH Lyon Sud, Pierre Benite, France
| | - O. Casasnovas
- Hopital Necker, Paris, France; Hopital Henri Mondor, Creteil, France; Hopital Saint Louis, Paris, France; Hopital Hotel Dieu, Paris, France; Institut Gustave Roussy, Villejuif, France; AZ Saint Jan, Brugge, Belgium; CHU Dijon, Dijon, France; Centre Henri Becquerel, Rouen, France; CH Lyon Sud, Pierre Benite, France
| | - H. Tilly
- Hopital Necker, Paris, France; Hopital Henri Mondor, Creteil, France; Hopital Saint Louis, Paris, France; Hopital Hotel Dieu, Paris, France; Institut Gustave Roussy, Villejuif, France; AZ Saint Jan, Brugge, Belgium; CHU Dijon, Dijon, France; Centre Henri Becquerel, Rouen, France; CH Lyon Sud, Pierre Benite, France
| | - G. Salles
- Hopital Necker, Paris, France; Hopital Henri Mondor, Creteil, France; Hopital Saint Louis, Paris, France; Hopital Hotel Dieu, Paris, France; Institut Gustave Roussy, Villejuif, France; AZ Saint Jan, Brugge, Belgium; CHU Dijon, Dijon, France; Centre Henri Becquerel, Rouen, France; CH Lyon Sud, Pierre Benite, France
| | - O. Hermine
- Hopital Necker, Paris, France; Hopital Henri Mondor, Creteil, France; Hopital Saint Louis, Paris, France; Hopital Hotel Dieu, Paris, France; Institut Gustave Roussy, Villejuif, France; AZ Saint Jan, Brugge, Belgium; CHU Dijon, Dijon, France; Centre Henri Becquerel, Rouen, France; CH Lyon Sud, Pierre Benite, France
| |
Collapse
|
48
|
Bienvenu J, Chvetzoff R, Salles G, Balter C, Tilly H, Herbrecht R, Morel P, Lederlin P, Solal-Celigny P, Audhuy B, Christian B, Gabarre J, Casasnovas O, Marit G, Sebban C, Coiffier B. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol J 2002; 2:378-84. [PMID: 11920277 DOI: 10.1038/sj.thj.6200133] [Citation(s) in RCA: 80] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/16/2001] [Accepted: 07/31/2001] [Indexed: 11/08/2022]
Abstract
INTRODUCTION In patients with low-grade non-Hodgkin's lymphoma, rituximab (MabThera) produces infusion-related toxicity, including fever, rigors, and chills in greater than 50% of those treated. The majority of these reactions are grade 1 or 2. MATERIALS AND METHODS In the GELA study LNH98-5, a total of 400 elderly patients with previously untreated diffuse large B-cell lymphoma were randomized to treatment with CHOP or with rituximab plus CHOP (R-CHOP). In a detailed investigation of biological events which may be associated with adverse reactions specific to rituximab infusion, a subgroup of 55 patients (26 in the CHOP group and 29 in the R-CHOP group) were selected for measurement of several biological parameters at baseline and at 1, 4 and 8 h (H1, H4 and H8, respectively) after commencing therapy. For 27 patients, measurements included cytokine and complement levels. RESULTS Baseline demographic and disease characteristics were similar for patients in both treatment groups. Compared with the CHOP treatment group, patients in the R-CHOP group had significantly higher post-treatment changes in neutrophil, lymphocyte, and monocyte counts, LDH levels, C3a levels, and TNF-alpha levels. In the R-CHOP group, neutrophil levels increased at H4 (P<0.05), lymphocyte levels decreased at H1 (P<0.05), H4 (P<0.001) and H8 (P<0.05), monocytes levels decreased at H1 (P<0.01), LDH levels increased at H4 (P<0.05) and H8 (P<0.01), and C3a decreased at H1 (P<0.01). The most statistically significant changes were observed for TNF-alpha levels: Mean values of TNF-alpha increased more than 250% at H1 and H4 and were still increased by 170% at H8 (P<0.001 at all timepoints). Since only six of the 55 evaluated patients had severe adverse events, it was not possible to correlate severe toxicity with these biological variations. CONCLUSION This analysis demonstrates that rituximab infusion was rapidly followed by activation of complement, B-lymphocyte cytolysis, and TNF-alpha release.
Collapse
Affiliation(s)
- J Bienvenu
- Laboratoire d'immunologie, CH Lyon-Sud, Pierre-Benite and Jeune Equipe 2267 from University Claude Bernard, Lyon, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Lévêque L, Bielefeld P, Piard F, Casasnovas O, Charmoille V. Gougerot-Sjögren primitif et lymphome T angiocentrique pulmonaire. Rev Med Interne 2001. [DOI: 10.1016/s0248-8663(01)80241-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
50
|
Caillot D, Couaillier JF, Bernard A, Casasnovas O, Denning DW, Mannone L, Lopez J, Couillault G, Piard F, Vagner O, Guy H. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19:253-9. [PMID: 11134220 DOI: 10.1200/jco.2001.19.1.253] [Citation(s) in RCA: 400] [Impact Index Per Article: 17.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE In patients with neutropenia, thoracic computed tomography (CT) halo and air-crescent signs are recognized as major indicators of invasive pulmonary aspergillosis (IPA). Nevertheless, the exact timing of CT images is not well known. PATIENTS AND METHODS Seventy-one thoracic CT scans were analyzed in 25 patients with neutropenia with surgically proven IPA. RESULTS On the first day of IPA diagnosis with early CT scan (d0), a typical CT halo sign was observed in 24 of 25 patients. At that time, the median number of thoracic lesions was two (range, one to six), and pulmonary involvement was bilateral in 12 cases. The halo sign was present in 68%, 22%, and 19% of cases on d3, d7, and d14, respectively. Similarly, the air-crescent sign was seen in 8%, 28%, and 63% of cases on the same days. Otherwise, a nonspecific air-space consolidation aspect was seen in 31%, 50%, and 18% of cases on the same days. The analysis of calculated aspergillary volumes on CT showed that, despite antifungal treatment, the median volume of lesions increased four-fold from d0 to d7, whereas it remained stable from d7 to d14. Overall, 21 patients (84%) were cured by the medical-surgical approach. CONCLUSION In patients with neutropenia, CT halo sign is a highly effective modality for IPA diagnosis. The duration of the halo sign is short, and it demonstrates the value of early CT. The increase of the aspergillosis size on CT in the first days after IPA diagnosis is not correlated with a pejorative immediate outcome when using a combined medical-surgical approach.
Collapse
Affiliation(s)
- D Caillot
- Department of Clinical Hematology, University Hospital of Dijon, Dijon, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|